0001179110-17-001096.txt : 20170119
0001179110-17-001096.hdr.sgml : 20170119
20170119204159
ACCESSION NUMBER: 0001179110-17-001096
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170117
FILED AS OF DATE: 20170119
DATE AS OF CHANGE: 20170119
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Innoviva, Inc.
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943265960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY
STREET 2: SUITE 500
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 6502389600
MAIL ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY
STREET 2: SUITE 500
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: THERAVANCE INC
DATE OF NAME CHANGE: 20020207
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Faerm Michael E.
CENTRAL INDEX KEY: 0001647141
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30319
FILM NUMBER: 17537362
MAIL ADDRESS:
STREET 1: C/O THERAVANCE, INC.
STREET 2: 951 GATEWAY BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
edgar.xml
FORM 4 -
X0306
4
2017-01-17
0
0001080014
Innoviva, Inc.
INVA
0001647141
Faerm Michael E.
2000 SIERRA POINT PARKWAY
SUITE 500
BRISBANE
CA
94005
0
1
0
0
Sr VP & Chief Business Officer
Common Stock
2017-01-17
4
A
0
133398
0
A
293607
D
Includes 66,698 shares of common stock granted pursuant to a time-based restricted stock award (RSA). Twenty-five percent of the shares subject to the RSA shall vest on February 20, 2018, and 6.25% of the shares subject to the RSA shall vest quarterly thereafter on the Issuer's standard vesting dates until February 20, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
Includes shares of common stock granted pursuant to a performance-based restricted stock award (PSA). The shares vest pursuant to the PSA over a two-year and three-year performance period upon, and subject to a formula related to, the Issuer's achievement of certain levels of relative total shareholder return (TSR). The "target" number of shares that may vest is 33,350 but the actual number of shares that may vest will range from 0 to 66,700 shares based on the Issuer's relative TSR over the performance periods. Subject to achievement of the performance-based vesting conditions, (i) two-thirds of the shares eligible to vest based on achievement for the two-year performance period will vest on February 20, 2019 and the remaining one-third of such shares will vest on February 20, 2020 and (ii) the share eligible to vest based on achievement for the three-year performance period will vest on February 20, 2020, in each case, (continued in Footnote 3)
(continued from Footnote 2) provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
Michael Faerm
2017-01-19